The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response

Int Immunopharmacol
January 2020
https://www.ncbi.nlm.nih.gov/pubmed/31835085

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization

Medical Sciences
21 September 2018
https://pdfs.semanticscholar.org/c495/7df14b181c4ae963a80fdeaf38c5cbb1a9e3.pdf?_ga=2.217655315.460139797.1583212532-762170649.1583212532

Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs)

Int Immunopharmacol
December 2013
https://www.ncbi.nlm.nih.gov/pubmed/24455776

The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol

Integr Cancer Ther
March 2006
https://www.ncbi.nlm.nih.gov/pubmed/16484716

Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck

Head Neck
April 2012
https://pubmed.ncbi.nlm.nih.gov/21584896/

Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system

Neuro Endocrinol Let
August 2002
https://pubmed.ncbi.nlm.nih.gov/12195238/

Severe pruritus of cholestasis in disseminated cancer: developing a rational treatment strategy. A case report

J Pain Symptom Manage
January 2005
https://www.sciencedirect.com/science/article/pii/S0885392404003914

Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer

Exp Biol Med
May 2013
https://pubmed.ncbi.nlm.nih.gov/23856908/

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway

Int Immunopharmacol
June 2020
https://pubmed.ncbi.nlm.nih.gov/32171145/?from_single_result=32171145&expanded_search_query=32171145

Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function

Altern Ther Health Med
05 November 2013
http://todayspractitioner.com/wp-content/uploads/2013/10/Bernard-Bihari-MD-Low-dose-Naltrexone-for-Normalizing-Immune-System-Function-athm_19_2_bihari_56_65.pdf